Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Diseases, Fort Collins, Colorado, USA.
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.03129-20.
Reported cases of tick-borne diseases have steadily increased for more than a decade. In the United States, a majority of tick-borne infections are caused by bacteria. Clinical diagnosis may be challenging, as tick-borne diseases can present with similar symptoms. Laboratory diagnosis has historically relied on serologic methods, which have limited utility during the acute phase of disease. Pathogen-specific molecular methods have improved early diagnosis, but can be expensive when bundled together and may miss unexpected or novel pathogens. To address these shortcomings, we developed a 16S rRNA gene PCR with a next-generation sequencing (NGS) approach to detect tick-borne bacteria in whole blood. A workflow was optimized by comparing combinations of two extraction platforms and two primer sets, ultimately pursuing DNA extraction from blood with the MagNA Pure 96 and PCR amplification using dual-priming oligonucleotide primers specific to the V1-V3 region of the 16S rRNA gene. The amplified product underwent modified Illumina 16S metagenomics sequencing library preparation and sequencing on a MiSeq V2 Nano flow cell, with data analysis using Pathogenomix RipSeq NGS software. Results with the developed method were compared to those from a V1-V2 16S rRNA gene primer set described by the Centers for Disease Control and Prevention (CDC). The V1-V3 assay demonstrated equivalent performance to the CDC assay, with each method showing concordance with targeted PCR results in 31 of 32 samples, and detecting 22 of 23 expected organisms. These data demonstrate the potential for using a broad-range bacterial detection approach for diagnosis of tick-borne bacterial infection from blood.
蜱传疾病的报告病例在过去十年中稳步增加。在美国,大多数蜱传感染是由细菌引起的。临床诊断可能具有挑战性,因为蜱传疾病的症状可能相似。实验室诊断历来依赖于血清学方法,但在疾病的急性期其应用有限。病原体特异性分子方法提高了早期诊断的能力,但当组合在一起时可能会很昂贵,并且可能会错过意想不到或新的病原体。为了解决这些缺点,我们开发了一种 16S rRNA 基因 PCR 与下一代测序(NGS)方法相结合,用于检测全血中的蜱传细菌。通过比较两种提取平台和两种引物组的组合,优化了工作流程,最终采用 MagNA Pure 96 从血液中提取 DNA,并使用针对 16S rRNA 基因 V1-V3 区的双引物寡核苷酸引物进行 PCR 扩增。扩增产物经过改良的 Illumina 16S 宏基因组测序文库制备和 MiSeq V2 Nano 流动池测序,使用 Pathogenomix RipSeq NGS 软件进行数据分析。将开发的方法的结果与疾病控制与预防中心(CDC)描述的 V1-V2 16S rRNA 基因引物组的结果进行比较。V1-V3 检测方法与 CDC 检测方法具有等效性能,每种方法在 32 个样本中的 31 个样本中与靶向 PCR 结果一致,并检测到 23 个预期生物中的 22 个。这些数据表明,使用广谱细菌检测方法从血液中诊断蜱传细菌感染具有潜力。